 Our research suggests that a novel peptid can be designed to target the SHP2 mutant, which could potentially be used as a therapeutic agent to treat cancer. This peptid has been shown to have increased binding affinity compared to the original peptid, suggesting that it could be more effective in inhibiting the spread of cancer cells. This article was authored by Mohamed Shahab, Shahin Shah Khan, Mariam Zulfat, and others.